High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F19%3A00078203" target="_blank" >RIV/00209805:_____/19:00078203 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/19:00108529
Result on the web
<a href="https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(19)30314-4" target="_blank" >https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(19)30314-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejca.2019.05.011" target="_blank" >10.1016/j.ejca.2019.05.011</a>
Alternative languages
Result language
angličtina
Original language name
High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact
Original language description
Abstract Purpose: The goal of our analysis was to study pretherapeutic circulating 25-OHD plasma levels in patients with previously untreated advanced gastric cancer treated in the randomised controlled phase III Erbitux (cetuximab) in combination with Xeloda (capecitabine) and cisplatin in advanced esophago-gastric cancer (EXPAND) trial (NCT00678535) and to explore whether low 25-OHD plasma levels are associated with worse prognosis and may compromise the clinical efficacy of cetuximab. Methods: Six hundred thirty patients with available pretherapeutic 25-OHD plasma levels and treated with chemotherapy based on capecitabine and cisplatin, or chemotherapy and cetuximab, were included. The Cox proportional hazard regression model was used to analyse the association between low 25-OHD and survival in both treatment arms. Results: Majority of study patients were found to have severe vitamin D deficiency. No prognostic impact of 25-OHD plasma levels could be found in our patient cohort, and there was no indication of an interference of 25-OHD plasma levels and the efficacy of treatment with the antieepidermal growth factor receptor monoclonal antibody cetuximab. Conclusions: Although majority of patients with advanced gastric cancer show hypovitaminosis D deficiency, there is no proof for a negative impact on survival or reduced treatment response. A prospective study is needed to investigate the potential benefit of vitamin D supplementation in this patient cohort during first-line chemotherapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European journal of cancer
ISSN
0959-8049
e-ISSN
—
Volume of the periodical
2019
Issue of the periodical within the volume
116
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
107-113
UT code for WoS article
000473270800013
EID of the result in the Scopus database
2-s2.0-85066947086